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In our paper, we discuss how the early phases of ankylosing spondylitis (AS) are
linked to peri-firbocartilagenous osteitis in the sacroiliac joint and entheseal bone related
anchoring sites. This skeletal proclivity is linked to an abnormal immunological response
to skeletal biomechanical stress and associated microdamage. A key event in the
early stages of AS appears to be the association with subclinical Crohn’s-like colitis
with this gut inflammation being pivotal to the osteitis reaction. Whether this osteitis
is consequent to non-specific intestinal innate immune activation or adaptive immune
responses against specific microbiotal or self-antigens is unknown. Recurrent iritis is an
HLA-B27 associated feature that may predate AS and pursues a course independent
of joint involvement, and points toward the pivotal role of organ specific immunology
over generalized systemic immune responses in disease expression. Human genetics
and animal model studies strongly incriminate the IL23/17 axis and TNF-α in disease
pathogenesis. Preliminary work shows a strong convergence of innate immune cells
including type 3 innate lymphoid-cells (ILC3) and γδ T-cells in skin, gut, entheseal,
and eye inflammation. Despite the HLA-B27 association, the role of adaptive immunity,
especially CD8+ T-cells mediated responses remains unproven and alternative theories
have been proposed. The emerging non-dependence of axial inflammation on IL-23 but
dependence on IL-17A is an unexpected new twist that awaits full explanation. In this
mini-review, we discuss the key events in the early stages of human AS from clinical and
basic science aspects, which could be crucial for attempted disease prevention studies
in at risk subjects.
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INTRODUCTION
Ankylosing spondylitis (AS) is the prototype of the inflammatory rheumatic diseases grouped
under the term spondyloarthritis (SpA) and represents the end phenotype of the axial SpA
group (1). The understanding of the male predominant, a late adolescent insidious onset of AS
with spinal involvement, characteristic extra-articular manifestations, and post inflammatory new
bone formation has remained relatively enigmatic (2). The pathogenesis of AS is not completely
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understood, but likely involves a complex interplay between
genetic predisposition involving the human leucocyte antigen,
namely HLA-B27, and environmental factors such as mechanical
stress and the microbiome (2, 3). In the last decade, imaging as
well as animal model studies have pointed toward enthesitis and
associated osteitis as the primary pathological process in SpA
including AS (4, 5) and we will thus focus on these early lesions.
The diagnosis of AS is determined according to the New York
criteria with the earlier pre-radiographic phases of AS defined
by the ASAS (Assessment of Spondylo-Arthritis International
Society) (6, 7), thus, we will focus on these pre-radiographic
phases since they may culminate in frank AS. Accordingly, this
early phase of disease includes nrAxSpA which may be evident
on MRI assessment and also includes the events that predate the
MRI lesions. The lack of a gold standard measure for predicting
AS such as AS-specific autoantibodies that may predate the
radiological or clinical presentation of SpA makes the early
disease phases virtually impossible to clearly discern, compared
to humoral associated autoimmune diseases like rheumatoid
arthritis (RA), or systemic lupus erythematosus (SLE) (8). Other
factors contributing to the difficulty in studying the early phases
of AS is the failure to recognize inflammatory back pain, and
the absence of visible swelling and often normal inflammatory
markers. The purpose of this perspective is to describe the events
that lead to disease initiation in the skeleton and extra-skeletal
sites in human AS.
THE INITIATION OF AS DISEASE AND
SKELETAL MECHANICS
Analogous to most of the autoimmune/autoinflammatory
diseases (9), the pathogenesis of AS is multifactorial and results
from a complex interplay between genetic predisposition and
environmental triggers (10). The modern understanding of
immune diseases classification that is especially relevant for
the rheumatic disorders, and is predicated on the concept
that disease may start in the primary and secondary lymphoid
organs, this type being autoimmune in nature, or may start in
the target tissues with tissue specific innate immune activation
and then secondary adaptive immune responses leading to
the clinical phenotype (11, 12). The pathological basis for AS
related inflammation affecting the anterior uveal tract, the aortic
root/valve, the lung apex, and enthesis organ structures including
sites of bone adjacent to entheseal and synovio-entheseal
fibrocartilages has been better conceptualized in relationship
to common biomechanical factors rather than autoimmunity
to a common antigen/autoantigen at these disparate sites (13)
(Figure 1). The strong tropism for the SpA associated uveitis to
occur in the “moving parts” of the anterior uveal tract and the
link between sonographically determined subclinical lower limb
enthesopathy and anterior uveitis points to the importance of
anterior uveal track biomechanics (14).
A key aspect of understanding the diverse pattern of organ
involvement in AS relates to the fact that mechanically stressed
disease prone sites are subject to recurrent tissue microdamage
(15, 16). For example, the aortic root and lung apex are both
recognized as target tissues in AS with these regions of the
body being subject to bleb formation and valvular damage,
respectively in other settings (16) (Figure 1). In the skeleton in
AS, there is a strong evidence that site specific localization of
disease is dependent on bone stressing. Clues to the cardinal
role of skeletal biomechanics come from pediatric HLA-B27-
related arthritis which has a propensity of midfoot and lower
limb enthesitis and oligoarthritis (17). With increasing age and
change in BMI and muscle structure, pediatric disease migration
with more topographic sacroiliac joints (SIJ), and subsequent
spinal involvement occurs, which mirrors the more common
pattern of young adult onset disease (17). This physical stressing
concept may also apply to the terminal ileum and bowel where
the hostile environment may be associated with spontaneously
healing apthous ulcerations in normal subjects (18) (Figure 1).
According to this biomechanical model of early AS, it would
be predicted that the target sites of AS including the SIJ and
axial and peripheral entheses would also exhibit similar MRI
patterns of bone oedema on skeletal stressing in subjects without
AS (13). Indeed this was first elegantly demonstrated in 2005
whereupon intense physical training in elite recruits developed
bone stressing responses around the skeleton, including SIJs and
in many cases, the lesions were asymptomatic (19). Interestingly,
these “injuries” healed or remained asymptomatic, despite the
continuation of intensive physical activity. Amore recent Belgian
study focussed on the SIJ and clearly showed transient physical
stress related bone marrow oedema patterns that were initially
reported as being a key feature of AS (20). Another recent paper
showed inferior SIJ bone oedema lesions were not uncommon in
elite athletes (21). Therefore, recurrent mechanical stress triggers
tissue microdamage and repair processes that occur exactly in the
same target sites as AS (Figure 2).
The question arises regarding the mechanism of new bone
formation in AS (a relatively late feature of disease) but not in
normal subjects that ostensibly experience the same biophysical
stressing. A genetic basis related to tissue remodeling differences
in AS is not compelling. Genetic polymorphisms in prostaglandin
receptor might be directly linked to an aberrant new bone
formation or downstream effect of IL-23 signaling on IL-
22 which in turn is known to drive skeletal stem cells (22).
Alternatively, the repair responses might be directly linked to
the magnitude of the preceding inflammation which in turn is
linked to the complex interplay between genetic susceptibility,
dysbiosis, and leaky gut to induce in SpA in comparison to
healthy subjects, wherein the latter a physiological level healing
of the tissue microdamage occurs.
Tissue microdamage has been clearly histologically
demonstrated in the spines of otherwise healthy subjects
from the third decade of age onwards with lesions having the
same topography of commonly viewed areas of MRI bone
oedema in AS (23). Ultrasound studies have also pointed toward
damage in normal entheses from young subjects without SpA
(24). Several studies show histological damage in normal spinal
and peripheral entheses in subjects without SpA (25) and also
microscopic inflammation in these tissues (26). Hence, there
is good evidence for microdamage and associated healing
responses in AS prone sites.
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FIGURE 1 | Heterogeneous AS disease localization sharing microanatomical features. Features of this figure are reproduced from https://smart.servier.com
(Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License), and were changed in terms of shape and size.
FIGURE 2 | Mechanical stress as a trigger of tissue microdamage and back pain and its consequences in those HLA-B27+ subjects with dysbyosis compared to
healthy subjects. Patients with AS have what is termed “inflammatory back pain” at the earliest stages of disease. However, skeletal microdamage that is viewed as
“non-inflammatory” has an initial inflammatory component to initiate removal of microdebris and tissue repair. Recognition that both early AS and non-AS back pain
shares the commonalities of skeletal biomechanical stress, microdamage and microinflammation for tissue repair helps explain why it is very difficult in many subjects
to accurately differentiate between inflammatory and “non-inflammatory” disease. Bone stressing reactions in AS and its juvenile genetically related equivalent occurs
at sites of complex compression and shearing and tensile forces. Innate immune dysregulation at such sites contributed to by gut barrier dysfunction may result in
entheseal immune activation. Subjects with HLA-B27 gene, dysbyosis and leaky gut are associated with adaptive immune activation and the characteristic early
disease MRI phenotype of osteitis. Features of this figure are reproduced from https://smart.servier.com (Servier Medical Art by Servier is licensed under a Creative
Commons Attribution 3.0 Unported License), and were changed in terms of shape and size.
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THE ROLE OF ENTHESIS TISSUE
ANATOMY IN EARLY STAGES OF AS
From a pathological perspective, AS skeletal involvement has
a strong propensity for peri-fibrocartilage osteitis in early SIJ
involvement and in later spinal involvement. Fibrocartilage
development dynamically occurs at sites of complex patterns of
skeletal stressing, including tension, and compression that occurs
at several synovial joints (SIJ, sternoclavicular, manubriosternal
and acromioclavicular joints) that are positioned perpendicular
to the ground and also entheses which share similar patterns
of biomechanical stress (15). Biomechanical testing studies have
shown that complex patterns of bone stressing are associated
with bone failure, so it is likely that this is key at sites of
simultaneous compressing and shearing forces on the skeleton
(27). The particular proclivity for AS peri-fibrocartilage related
osteitis in the SIJs, wrap around tendons and in the bone at
entheseal anchorage sites has been reviewed previously (15, 28).
Thus, peri-fibrocartilageneous bone and entheses represent a
primary site and tissue target where innate and adaptive reactions
occur initially as a repair process, but in later phases can result
in remodeling effects including bone oedema, osteitis, new bone
formation, and in some cases spine fusion in those genetically
predisposed (Figure 3). Such predispositions include carriage
of HLA-B27 gene with associated abnormal gut permeability,
with a ramped up inflammatory response with a subsequent
post inflammation excessive repair reaction that may ultimately
culminate in ankylosis (1).
INSIGHT AND LESSONS LEARNT FROM
IMAGING STUDIES IN EARLY PHASES OF
AS
It is known from MRI studies that carriage of the HLA-B27 gene
is a risk factor for the extent and chronicity of bone marrow
oedema lesions, histologically classed as osteitis, in the SIJ in
AS (29). Likewise, it has been shown that HLA-B27+ axial PsA
subjects have a much greater degree of MRI determined axial
osteitis compared to axial disease in HLA-B27- subjects (30).
Furthermore, the severity of peripheral skeletal involvement in
SpA related heel disease is linked to a carriage of the HLA-
B27 gene which is of a greater magnitude than the mechanically
driven disease (29). Patients with early inflammatory back pain
and a combination of severe sacroiliitis and HLA-B27 positivity
are at higher risk for development of AS, compared with
mild or no sacroiliitis, regardless of HLA-B27 status (31). The
role of adaptive immunity in the clinical expression of AS
in the trabecular bone seems likely based on disease MHC-
I associations, most notably HLA-B27 but also HLA-B40, in
addition to several other genes involved in T-cell biology (12, 32).
THE IMPORTANCE OF THE GUT IN EARLY
AS
Up to 10% of AS patients are reported to have IBD and 70% shows
signs which indicate subclinical intestinal inflammation (33).
From genome wide association studies (GWAS), it is evident
that over 10% of the gene pathways are shared between IBD
and AS (34). An important recent study showed a clear link
between the severity of subclinical gut inflammation and MRI
determined SIJ involvement (20). It has long been suggested that
intrinsic barrier dysfunction permits non-specific innate immune
activation with systemic translocation of bacterial adjuvants (16).
In AS, the tight junctions between intestinal epithelial cells are
prone to increased permeability and this is termed a leaky gut
(35, 36). Several molecules increased in AS may point toward the
idea of a leaky gut such as LPS-binding protein, fatty acid binding
protein and zonulin (37–39). In recent times, specific alterations
into the composition of the gut microbiota, rather than the non-
specific innate activation theory have emerged and have been
associated with a range of immune mediated disorders (39).
It has been postulated that carrying HLA-B27 is predisposing
for gut dysbiosis followed by a leaky gut and subsequent
systemic entrance of microbial antigens and adjuvants, which
may act as a trigger for enthesitis. These adjuvants may activate
entheseal stromal and immune resident cell populations leading
to the activation of the IL-23/IL-17 axis, secretion of pro-
inflammatory cytokines resulting in enthesitis, osteitis and joint
local inflammation (40, 41).
GENETIC INFLUENCES IN EARLY AS
The genetics of AS including the striking HLA-B27 is well
recognized and reviewed elsewhere and is only briefly discussed
here (42, 43). The carriage of HLA-B27 gene in AS is well-
established and varies according to the populations (44–46) with
other MHC-I antigens, most notably HLA-B40 being linked
to disease (47). Up to 167 subtypes of HLA-B27 have been
reported, with those not associated with AS typically having
structural changes within the amino acid peptide binding groove
(48), which may support the concept of antigen presentation in
disease. Less than 5% of those positive for HLA-B27 ever develop
AS, pointing toward other key genes and other factors influencing
early disease susceptibility (49).
GWAS studies have also shown that SNPs in ERAP-1 in
epistatic interaction with HLA-B27 are common in AS (47, 50).
ERAP-1 interactions with HLA-B40 have also been shown in AS
and it is noteworthy that ERAP-1 is involved in peptide trimming
for T-cell presentation. RUNX3 SNPs has been reported in AS,
combined with epigenetic regulation at the RUNX3 locus in
CD8+ T-cells, which affects their differentiation in AS (51,
52). Thus, MHC-I, ERAP-1, and RUNX3 SNPs in AS strongly
incriminate antigen presentation and adaptive CD8+ T-cell
responses in disease pathogenesis (53, 54). Recent structural
biology results showed that AS-associated HLA–B∗27 subtypes
B∗27:04 and B∗27:05 possessed elevated molecular dynamics
compared to the non-associated sub- types B∗27:06 and B∗27:09
which further incriminates classical peptide presentation to
cytotoxic T-cells (55).
However, unlike the MHC-I associated disease psoriasis,
where putative autoantigens have been defined, specific antigens,
either self, or foreign that drive disease have not been defined
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FIGURE 3 | Different phases of the immunopathogenesis of AS. The interaction between different components considered as risk factors for AS leads to innate
immunity dysregulation in the spinal entheses and other sub-fibrocartilagenous bone. Local secretion if IL-23 and activation of ILC3 and in later phase to adaptive
immunity dysregulation with activation of IL-23R positive immune cells such as γδ T-cells and other unknown cells releasing IL-17 that results in remodeling effects
including bone oedema, osteitis, new bone formation and in some cases spine fusion. Features of this figure are reproduced from https://smart.servier.com (Servier
Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License), and were changed in terms of shape and size.
(56). This remains the biggest black box to be elucidated in early
AS disease pathogenesis.
The failure to define classical adaptive immune responses
in early AS, despite the growing indirect evidence for such a
mechanism has resulted in research into alternative mechanisms.
CD4+ T-cells are also thought to play a role in AS with CD4+ T-
cells capable of recognizing and binding to misfolded HLA-B27
(57). Misfolding of HLA-B27 proteins with an unfolded protein
response and ER stress also leads to macrophage activation with
increased IL-23 induction, supporting a potential link between
HLA-B27 misfolding and immune dysregulation (58). However,
whilst ASHLA-B27 blood derivedmacrophages have been shown
to secrete increased IL-23 when compared to healthy patients, it
is thought this is independent of ER stress (59). Moreover, it was
reported that dimers of HLA-B27 have been shown to promote
survival of subsets of natural killer (NK) and CD4+ Th17 T-cells
expressing KIR3DL2 (60).
BASIC AND TRANSLATIONAL CYTOKINE
IMMUNOLOGY OF AS
The role of TNF-α in experimental SpA models that have
oligoarthritis and sacroiliitis is well-established and these models
are mechanically dependent (61). The normal human spinal
entheses harbor type 3 ILCs IL-23R expressing cells, capable
of IL-17 production, and are therefore also potential mediators
of IL-23 driven enthesitis (62). However, although monocytes
and macrophages are known to produce IL-23, the source of
IL-23 acting at the enthesis remains to be fully elucidated but
evidence for local myeloid production has been reported (63).
Regarding immune cells and the previously mentioned IL-23/IL-
17 axis, IL-17 producing ILC3 cells are more prevalent in the
gut of AS patients when compared to healthy controls, with
the highest correlation pointing toward the inflamed gut of
AS patients (64). This adds weights to the growing theory of
a possible gut-bone axis and a gut-inflammation-spondylitis
link, with both IL-23/IL-17 and HLA-B27 acting as central
players (65). The interaction between HLA-B27 and the IL-
23/IL-17 is incompletely understood but may be linked to
activation of Tc17 cells (CD8+ T-cells that produce IL-17) (66,
67). However, it has also been suggested that classical peptide
presentation by HLA-B27 activates myeloid dendritic cells that
subsequently drive a Tc17 adaptive immune response that is
antigen dependent (12). We favor this classical model which
was also touted and reinvigorated following the discovery of
ERAP-1 SNPs in AS, especially given that this ERAP-1 is key to




IL-17 production that is independent of IL-23 is potentially
crucial in the maintenance of AS (68) and IL-23 inhibition has
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no clear clinical benefit in established AS (69). Stromal cells have
been shown to mediate the inflammatory response to mechanical
stress (61) and have been shown to directly stimulate Th-17
production of IL-17 in an IL-23 independent manner by the
release of prostaglandin E2 (PGE2) (70). In the gut, PGE2 is
expressed constitutively and is crucial for homeostasis.
The γδ T-cells group form a multifaceted subset of cells
that have a crucial role in gut homeostasis and have also
been shown to produce IL-17 independently of IL-23 (71).
There is a growing body of evidence to suggest that different
entheseal cell populations such as γδ T-cells are key players
in SpA pathogenesis and this may be IL-23 dependent or
independent but the potential contribution of multiple cell types
cannot be ignored. Recently it was experimentally shown that
IL-23 is essential for the initiation of SpA, but not disease
progression since the triggering of IL-17A and IL-22 resulted
in independent disease progression (68). It has also been
reported that macrophages from AS patients have a greater IL-
23 secretory ability (59, 72). IL-17 producing cells have been
confirmed in AS facet joints (73). Whilst the IL-23/IL-17 axis
was thought to be once involved in both RA and SpA, clinical
reports now suggest this axis is of more central importance
in PsA and axial SpA such as AS (67). In the context of AS
immunopathology, IL-22 may activate osteoproliferation (22). It
should be emphasized that themajority of IL-17 studies in human
AS have focused on established disease and not early stages,
thus the relative importance of different immune pathways into
disease initiation and progression are not known. In line with
this point, it was is thus surprising that risankizumab a IL-
23p19 inhibitor failed to show efficacy in AS (69), whereas
secukinumab (anti IL-17) showed efficacy (74). Furthermore,
the IL-12p40 blocking antibody ustekinumab, which also blocks
IL-23 failed to show efficacy in 3 phase 3 clinical trials in AS,
although the full results have not been published. However,
a previous open-label study of ustekinumab in AS showed
responses at week 24 (75). It is possible that IL-17 production
in the spine that is independent of IL-23 signaling might be
sufficient to drive disease, the opposite scenario to the gut where
IL-17 production independent of IL-23 protects from disease,
namely colitis. ILC3s are also emerging potential immune
regulators of AS, capable of producing IL-17 and found to be
expanded in the intestinal, synovial fluid, peripheral blood, and
bone marrow of AS patients (64) and at the normal human
enthesis (62).
LESSONS LEARNED FROM ANIMAL
MODEL STUDIES
Animal models have already been well-reviewed elsewhere and
the focus of this article is on early human disease (76, 77).
Transgenic mice and rats for HLA-B27 are known to develop
spontaneous inflammatory diseases similar to humans such
as SpA (78, 79). Other studies also highlight that HLA-B27
transgenic rats show an altered gut microbiota (80). A recent
paper, using HLA-B27 rat model showed that spondyloarthritis
pathology, is dependent on IL-23 for initiation but not
persistence (68). This may indeed point toward the idea of IL-17
production that is independent of IL-23 in disease progression,
whilst IL-23 is required for disease initiation. However, inhibition
of IL-23 and IL-12 in dendritic cells in mice is shown to protect
against T-cell immune mediated diseases (81). Different animal
model studies of SpA are pointing toward a prominent role
of local innate immunity originating due to local tissue injury
as a component of tissue repair that in later phases leads to
dysregulation of adaptive immunity (5). However, some models
demonstrated an enhanced IL-17 production from naïve CD4+
T-cells, which are generated from a depleted number ofmigratory
dendritic cells (82, 83). Th17 cells also promote the formation
of IL-12/IL-23 producing dendritic cells, suggesting a cycling
inflammatory pathway. IL-23 overexpression in mice causes a
florid enthesitis which is driven by enthesis resident population
of IL-23R positive innate T-cells that drove IL-17A dependent
pathology (77). The primary source of IL-17 in this model were
γδ T-cells rather than conventional αβ T-cells including Th-
17 cells (84). The predominant subtype involved was the Vγ6
subset which has also been shown to invade sites of bone injury
and contribute to repair via the production of IL-17 in an
independent unrelated bone fracture model (85).
CONCLUSION
We focused on the early phases of AS, where skeletal mechanical
responses to stress and gut dysfunction, whether related to the
microbiome, or specific microbes or simply intrinsic barrier or
mucosal immune dysfunction are important. The TNF-α and
the IL-17 pathways remain cardinal but unexpectedly, IL-23
does not have a role in established AS but may play a pivotal
role in the early phases of AS. Further studies on early phases
of AS are needed to elucidate different immunopathological,
translational, and therapeutic aspects. The current immunology
supports the concept of different innate immune cell populations
being present in virtually all of the skeletal and extra-skeletal
target sites of AS. Some of these cytokines clearly play a protective
role in tissue homeostasis best exemplified for IL-17A in the gut.
Other molecules including PGE2 are physiologically involved in
tissue repair. The over exuberant repair responses and chronic
bone formation phenotypes in established AS suggest that
post inflammatory over exuberant repair responses might link
dysregulated cytokine pathways leading to a new bone formation.
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